Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis

Autor: Anne-Sofie Halling, Maria Rasmussen Rinnov, Iben Frier Ruge, Trine Gerner, Nina Haarup Ravn, Mette Hjorslev Knudgaard, Simon Trautner, Nikolai Loft, Lone Skov, Simon F. Thomsen, Alexander Egeberg, Emma Guttman-Yassky, Aske L.L. Rosted, Troels Petersen, Ivone Jakasa, Sanja Kezic, Jacob P. Thyssen
Přispěvatelé: Public and occupational health, AII - Infectious diseases, APH - Personalized Medicine, APH - Societal Participation & Health
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal of allergy and clinical immunology. Mosby Inc.
ISSN: 0091-6749
Popis: Background: It is unknown whether skin biomarkers collected in infancy can predict the onset of atopic dermatitis (AD) and be used in future prevention trials to identify children at risk. Objectives: This study sought to examine whether skin biomarkers can predict AD during the first 2 years of life. Methods: This study enrolled 300 term and 150 preterm children at birth and followed for AD until the age of 2 years. Skin tape strips were collected at 0 to 3 days and 2 months of age and analyzed for selected immune and barrier biomarkers. Hazard ratio (HR) with 95% confidence interval (CI) using Cox regression was calculated for the risk of AD. Results: The 2-year prevalence of AD was 34.6% (99 of 286) and 21.2% (25 of 118) among term and preterm children, respectively. Skin biomarkers collected at birth did not predict AD. Elevated thymus- and activation-regulated chemokine/C-C motif chemokine ligand 17 -levels collected at 2 months of age increased the overall risk of AD (HR: 2.11; 95% CI: 1.36-3.26; P = .0008) and moderate-to-severe AD (HR: 4.97; 95% CI: 2.09-11.80; P = .0003). IL-8 and IL-18 predicted moderate-to-severe AD. Low filaggrin degradation product levels increased the risk of AD (HR: 2.04; 95% CI: 1.32-3.15; P = .001). Elevated biomarker levels at 2 months predicted AD at other skin sites and many months after collection. Conclusions: This study showed that noninvasively collected skin biomarkers of barrier and immune pathways can precede the onset of AD.
Databáze: OpenAIRE